Glucosamine
An amino sugar sold for knee osteoarthritis, with one of the most divided evidence bases of any supplement. Trials of a single prescription crystalline glucosamine sulfate product are positive; trials of other products, of glucosamine hydrochloride, and every industry-independent trial pooled together find little or nothing over placebo. US rheumatologists strongly recommend against it; a European society recommends the prescription sulfate. If you try it, use crystalline sulfate at 1,500 mg once daily for 12 weeks and stop if nothing changes.
Medical Disclaimer: The information on this page is for educational and research purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
What Glucosamine Is
Glucosamine is an amino sugar the body uses to build glycosaminoglycans, the long chains that hold water in cartilage. Supplements are made from shellfish shells or by fermentation and come in two main salts: glucosamine sulfate, sold in Europe as a crystalline prescription product, and glucosamine hydrochloride, the common US supplement form. The theory is that extra substrate supports cartilage repair. Whether that happens in a human knee is what three decades of trials have argued about.
Absorption
Taken by mouth at 1,500 mg once a day, crystalline glucosamine sulfate reaches a peak plasma level of about 10 µM, and plasma levels rise in proportion to dose from 750 to 1,500 mg but not at 3,000 mg. In 12 people with osteoarthritis who took 1,500 mg a day for 14 days, synovial fluid glucosamine reached a median 777 ng/mL, about 20 times baseline. Both pharmacokinetic studies were run by the manufacturer of the crystalline product. The drug reaches the joint; what it does there is the open question.
What the Trials Show
The evidence splits cleanly along two lines: which product and who paid.
- The crystalline sulfate trials are positive. Over three years in 212 people, joint-space loss was −0.31 mm on placebo and −0.06 mm on glucosamine sulfate. A second three-year trial in 202 people found joint-space narrowing of −0.19 mm on placebo against +0.04 mm on glucosamine, with symptoms 20–25% better. A six-month trial in 318 people found glucosamine sulfate beat placebo on the Lequesne index (−3.1 vs −1.9) while acetaminophen did not. Manufacturer scientists were co-authors on these trials.
- Other products are not. A meta-analysis of 25 trials found that the brand explained 41% of the variation in results: the crystalline sulfate trials pooled to an effect size of −1.07, other products to −0.11, which is no effect. Even within the crystalline trials, the three at low risk of bias gave −0.27. The 2005 Cochrane review saw the same split.
- Independent trials find nothing. The NIH-funded GAIT trial in 1,583 people with knee pain found glucosamine hydrochloride 3.9 points better than placebo on response rate, not significant, against a 60.1% placebo response. An individual-patient meta-analysis of the industry-independent trials, 1,625 people, found glucosamine no better than placebo at 3 or 24 months in any subgroup. In hip osteoarthritis, two years of crystalline sulfate made no difference.
The long-form read on all of this is Glucosamine and Chondroitin for Knee Osteoarthritis: What 20 Years of Trials Show. The NIH trial is broken down in The 1,583-Person NIH Trial That Tested Glucosamine Against Celecoxib.
What the Guidelines Say
They disagree, and the disagreement is the evidence split above. The 2019 American College of Rheumatology and Arthritis Foundation guideline strongly recommends against glucosamine for knee, hip and hand osteoarthritis. It notes that pharmaceutical-grade glucosamine was studied in multiple trials, but that the gap between industry-sponsored and publicly funded results raised serious concerns about publication bias, and that the lowest-bias data showed no important benefit over placebo. The 2014 algorithm from the European society ESCEO puts prescription crystalline glucosamine sulfate in step one of knee osteoarthritis care. Both groups agree on the foundation: exercise, weight loss and education come first.
Dose and Form
If you try it: 1,500 mg of crystalline glucosamine sulfate, once a day, with food, for 12 weeks. That is the dose and form of every positive trial. Hydrochloride at the same dose is what the null NIH trial used. Doubling the dose does not double the blood level. Record a pain and function score before you start, and stop at 12 weeks if it has not moved more than it would on placebo; in osteoarthritis trials the placebo response alone is large.
Safety
Glucosamine is well tolerated; side effects in the large trials were similar to placebo. Two issues deserve attention. Warfarin: there are 20 FDA MedWatch and 21 WHO reports of a raised INR, 17 of 21 resolving when glucosamine stopped, and a published case where the INR climbed from 2.3 to 4.7 after the dose was raised. Glucose: a review of 11 studies found 4 that reported lower insulin sensitivity or higher fasting glucose, mostly in people already insulin resistant, while a 6.5-year analysis of a prevention trial in 407 overweight women found no effect on HbA1c or new diabetes. Shellfish-allergic volunteers tolerated a 1,500 mg challenge.
Large UK Biobank cohorts link habitual glucosamine use with lower all-cause mortality (hazard ratio 0.85). That is an association in people who choose to take supplements, not evidence that glucosamine extends life.
Where It Fits
Glucosamine is one of the choices in Layer 1 of the Knee Osteoarthritis Supplement Trial, introduced only after the exercise and weight layer and run alone for 12 weeks. It is compared with chondroitin and undenatured type II collagen in the protocol's guide, and the anti-inflammatory alternatives are curcumin and boswellia.
Stacking Interactions
How Glucosamine interacts with other compounds
One six-month trial of the combination found it worse than placebo for pain; another found it non-inferior to celecoxib with no placebo arm. Try one at a time so you can tell what worked
The short-term pain evidence for turmeric extracts is stronger than for glucosamine. If you only try one supplement for knee pain, the trials favour turmeric
The supplier-funded UC-II trial included a glucosamine-plus-chondroitin arm, and UC-II scored better than it
Protocols using Glucosamine
Evidence-graded stacks that include this compound
Safety Profile — Tier A
Well-tolerated — strong human evidence
Contraindications
- ●Warfarin or other vitamin K antagonists — increased INR and bleeding have been reported; avoid, or only with INR monitoring agreed with the prescriber
- ●Diabetes or impaired glucose tolerance — evidence on glucose is mixed; check fasting glucose or HbA1c if you continue beyond 12 weeks
- ●Pregnancy and breastfeeding — not studied
Side Effects
- ●Mild gastrointestinal upset, nausea, heartburn, diarrhea — similar to placebo in the large trials
- ●Headache and drowsiness, uncommon
- ●Shellfish allergy: in a challenge study, 15 shrimp-allergic people tolerated 1,500 mg; synthetic or plant-derived products remove the question
Drug Interactions
Research References
- [1]PubMed: 16495392
- [2]PubMed: 11214126
- [3]PubMed: 12374520
- [4]PubMed: 17265490
- [5]PubMed: 18283204
- [6]PubMed: 24905534
- [7]PubMed: 15846645
- [8]PubMed: 28754801
- [9]PubMed: 20847017
- [10]PubMed: 31908163
- [11]PubMed: 24953861
- [12]PubMed: 18363538
- [13]PubMed: 17083356
- [14]PubMed: 21251987
- [15]PubMed: 28011309
- [16]PubMed: 32253185
- [17]PubMed: 16168682
- [18]PubMed: 17353133